Scholarlink

Background <p>Automatic substitution of biological medicines was introduced in Finnish community pharmacies in 2024, including glargine insulins in 2025. Patient views on this policy have mainly been studied with other patients than&#xa0;people with diabetes (PwD). Unlike other biological medicines, insulin has a narrow therapeutic window, carries risk of hypoglycemia and hyperglycemia, and requires patient-directed dose adjustments. Therefore, it is essential to explore the views of PwD regarding automatic substitution.</p> Objectives <p>To investigate the concerns of insulin-treated PwD regarding the automatic substitution of insulins, their knowledge and information needs related to biological medicines, biosimilars, and automatic substitution, and the factors associated with this knowledge.</p> Methods <p>An electronic survey was conducted in May 2024. Chi-squared test and binary logistic regression were used to examine the association between participant characteristics and outcome variables.</p> Results <p>Among the 459 participants, 62% expressed concerns about whether the substituted insulin would be as good as the insulin previously used and about the expertise of pharmacists (47%) and physicians (46%). Awareness of biological medicines (67%) exceeded awareness of automatic substitution (45%) and biosimilars (38%), although 63% correctly identified the definition of a biosimilar. Inferior knowledge was associated with higher HbA1c, fewer comorbidities, shorter long-acting insulin use, male gender, age over 70, and use of long-acting insulin as part of multiple daily injections. Over half (55%) reported needing more information.</p> Conclusions <p>Awareness of biosimilars and automatic substitution of biological medicines was limited among PwD. These findings underscore the importance of targeted communication and education to ensure medically safe substitutions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biological Medicines, Biosimilars and Their Automatic Substitution: Concerns, Knowledge and Information Needs of People with Diabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Marianne Kouhia,
  • Kari Linden,
  • Saara Metso,
  • Elina Pimiä,
  • Sari Koski,
  • Emma Aarnio,
  • Tuomas Zacheus,
  • Katri Hämeen-Anttila

摘要

Background

Automatic substitution of biological medicines was introduced in Finnish community pharmacies in 2024, including glargine insulins in 2025. Patient views on this policy have mainly been studied with other patients than people with diabetes (PwD). Unlike other biological medicines, insulin has a narrow therapeutic window, carries risk of hypoglycemia and hyperglycemia, and requires patient-directed dose adjustments. Therefore, it is essential to explore the views of PwD regarding automatic substitution.

Objectives

To investigate the concerns of insulin-treated PwD regarding the automatic substitution of insulins, their knowledge and information needs related to biological medicines, biosimilars, and automatic substitution, and the factors associated with this knowledge.

Methods

An electronic survey was conducted in May 2024. Chi-squared test and binary logistic regression were used to examine the association between participant characteristics and outcome variables.

Results

Among the 459 participants, 62% expressed concerns about whether the substituted insulin would be as good as the insulin previously used and about the expertise of pharmacists (47%) and physicians (46%). Awareness of biological medicines (67%) exceeded awareness of automatic substitution (45%) and biosimilars (38%), although 63% correctly identified the definition of a biosimilar. Inferior knowledge was associated with higher HbA1c, fewer comorbidities, shorter long-acting insulin use, male gender, age over 70, and use of long-acting insulin as part of multiple daily injections. Over half (55%) reported needing more information.

Conclusions

Awareness of biosimilars and automatic substitution of biological medicines was limited among PwD. These findings underscore the importance of targeted communication and education to ensure medically safe substitutions.